iCAD (NASDAQ:ICAD – Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, August 13th.
iCAD (NASDAQ:ICAD – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The technology company reported ($0.05) earnings per share for the quarter. The business had revenue of $4.95 million during the quarter. iCAD had a negative return on equity of 14.00% and a negative net margin of 15.20%.
iCAD Trading Down 5.5 %
Shares of ICAD opened at $1.20 on Wednesday. The business’s 50 day moving average is $1.37 and its 200 day moving average is $1.50. iCAD has a 12-month low of $1.18 and a 12-month high of $2.78. The company has a market capitalization of $31.85 million, a PE ratio of -10.00 and a beta of 1.50.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
- Five stocks we like better than iCAD
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Lumen’s Q2: Can AI Revenue Outshine a Mountain of Debt?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Carry Trade Ending: Recent Market Turbulence and Future Risks
- Stock Analyst Ratings and Canadian Analyst Ratings
- Stocks Slide: Trillions Lost, More Downside Ahead?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
